NASDAQ:IDRA Idera Pharmaceuticals (IDRA) Stock Price, News & Analysis → These AI trades triggered this morning (545% return) (From Prosper Trading Academy) (Ad) Free idra Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$0.17▼$7.2352-Week Range N/AVolume21,870 shsAverage Volume464,030 shsMarket Capitalization$450.52 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Idera Pharmaceuticals alerts: Email Address Ad Insiders ExposedThe Hard Truth About Investing For RetirementHere’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.Click To Access This Powerful Training Right Now! About Idera Pharmaceuticals Stock (NASDAQ:IDRA)Aceragen, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Exton, PA.Read More Ad Insiders ExposedThe Hard Truth About Investing For RetirementHere’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.Click To Access This Powerful Training Right Now! IDRA Stock News HeadlinesApril 11, 2024 | fool.comEkso Bionics (NASDAQ: EKSO)November 15, 2023 | forbes.comKiniksa PharmaceuticalsApril 25, 2024 | TradeSmith (Ad)The A.I. story nobody is telling you (Read ASAP)There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...August 9, 2023 | investing.comNabriva Therapeutics AG (NBRVF)April 26, 2023 | npr.orgMarginaliaMarch 17, 2023 | washingtonpost.comA mysterious rift propels the story in ‘Take What You Need’January 18, 2023 | finanznachrichten.deIdera Pharmaceuticals, Inc.: Idera Pharmaceuticals Announces Name Change to Aceragen, Inc. and Provides Near-Term Strategic OutlookJanuary 17, 2023 | finance.yahoo.comIdera Pharmaceuticals Announces Name Change to Aceragen, Inc. and Provides Near-Term Strategic OutlookApril 25, 2024 | Insiders Exposed (Ad)The Hard Truth About Investing For RetirementHere’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.January 10, 2023 | msn.comWhy Bed Bath & Beyond Shares Are Trading Higher By 17%? Here Are Other Stocks Moving In Tuesday's Mid-Day SessionJanuary 4, 2023 | thestreet.comIdera (IDRA) Stock Soars on GlaxoSmithKline PartnershipNovember 18, 2022 | finanznachrichten.deIdera Pharmaceuticals, Inc.: Idera Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateNovember 14, 2022 | finance.yahoo.comIdera Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateSeptember 29, 2022 | finance.yahoo.comIdera Pharma Acquires Rare Disease Player, Names New CEOSeptember 28, 2022 | marketwatch.comIdera Pharma Shares Rise Nearly 18% After Aceragen AcquisitionSeptember 28, 2022 | finance.yahoo.comIdera Pharmaceuticals Acquires AceragenSeptember 27, 2022 | benzinga.comIdera Pharmaceuticals Stock (NASDAQ:IDRA), DividendsAugust 9, 2022 | finance.yahoo.comIdera Pharmaceuticals Reports Second Quarter 2022 Financial ResultsMay 17, 2022 | seekingalpha.comIdera halts melanoma trial for cancer candidate after early positive resultsMay 17, 2022 | finance.yahoo.comWhy Are Idera Pharmaceuticals Shares Soaring TodayMay 17, 2022 | finance.yahoo.comIdera Pharmaceuticals Shares Positive Results from Investigator-Sponsored Trial in Melanoma Patients at Amsterdam UMCMay 5, 2022 | finance.yahoo.comIdera Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate UpdateMarch 31, 2022 | finance.yahoo.comIdera Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate UpdateDecember 15, 2021 | msn.comIdera Shares Fall After Early Tilsotolimod Data, Seeks Collaborating Partners For TLR9 AgonistDecember 14, 2021 | finance.yahoo.comIdera Pharmaceuticals Announces Tilsotolimod UpdatesDecember 8, 2021 | chron.com5 Penny Stocks To Buy According To Analysts & Targets Up To 341%November 8, 2021 | finance.yahoo.comIdera Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate UpdateSee More Headlines Receive IDRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Idera Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/08/2021Today4/25/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:IDRA CUSIPN/A CIK861838 Webwww.iderapharma.com Phone(484) 348-1600Fax617-679-5592Employees32Year Founded1989Profitability EPS (Most Recent Fiscal Year)($0.32) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$98.09 million Net MarginsN/A Pretax MarginN/A Return on Equity-68.74% Return on Assets-34.26% Debt Debt-to-Equity RatioN/A Current Ratio1.56 Quick Ratio1.56 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash Flow0.29 Book Value$0.56 per share Price / BookN/AMiscellaneous Outstanding Shares62,355,000Free Float59,206,000Market Cap$450.52 million OptionableOptionable Beta1.25 Social Links 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. John J. Kirby CPA (Age 50)Chief Financial Officer Comp: $477.41kMr. Bryant David Lim (Age 51)Chief Bus. Officer & Gen. Counsel Comp: $480.96kMr. John C. Taylor (Age 52)CEO & Director Mr. Daniel Salain (Age 55)Chief Operating Officer Mr. Andy Jordan (Age 75)Chief Strategy Officer Dr. Carl Kraus M.D. (Age 53)Chief Medical Officer Dr. Shah Rahimian M.D.Ph.D., Medical Director & Global Clinical Lead for OncologyDr. Joanna Caroline Horobin Ch.B (Age 67)M.B., Advisor Dr. Sudhir Agrawal D.Phil. (Age 68)F.R.S.C., Scientific Advisor Mr. Louis J. Arcudi III (Age 61)M.B.A., MBA, Adviser More ExecutivesKey CompetitorsEditas MedicineNASDAQ:EDITHumacyteNASDAQ:HUMATaysha Gene TherapiesNASDAQ:TSHAC4 TherapeuticsNASDAQ:CCCCAlvotechNYSE:ALVOView All Competitors IDRA Stock Analysis - Frequently Asked Questions How were Idera Pharmaceuticals' earnings last quarter? Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) posted its earnings results on Monday, November, 8th. The biotechnology company reported ($0.06) earnings per share for the quarter, topping analysts' consensus estimates of ($0.06) by $0.01. When did Idera Pharmaceuticals' stock split? Idera Pharmaceuticals shares split before market open on Friday, November 25th 2022. The 2-1 split was announced on Friday, November 25th 2022. The newly created shares were issued to shareholders after the closing bell on Friday, November 25th 2022. An investor that had 100 shares of stock prior to the split would have 200 shares after the split. What is Vincent Milano's approval rating as Idera Pharmaceuticals' CEO? 7 employees have rated Idera Pharmaceuticals Chief Executive Officer Vincent Milano on Glassdoor.com. Vincent Milano has an approval rating of 88% among the company's employees. What other stocks do shareholders of Idera Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Idera Pharmaceuticals investors own include Oasis Petroleum (OAS), BioCryst Pharmaceuticals (BCRX), Sorrento Therapeutics (SRNE), Novavax (NVAX), Dynavax Technologies (DVAX), Proteostasis Therapeutics (PTI), Geron (GERN), Rigel Pharmaceuticals (RIGL), Inovio Pharmaceuticals (INO) and Anavex Life Sciences (AVXL). This page (NASDAQ:IDRA) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldHe Is Giving Away BitcoinCrypto Swap ProfitsYour Money is Not SafeAmerican Alternative Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Idera Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
